Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Growth in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 3,100,000 shares, a growth of 29.2% from the January 31st total of 2,400,000 shares. Currently, 15.1% of the company’s stock are short sold. Based on an average daily volume of 327,700 shares, the short-interest ratio is presently 9.5 days.

Analyst Ratings Changes

Separately, Morgan Stanley dropped their target price on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, February 3rd.

Insider Buying and Selling at Fractyl Health

In related news, insider Jay David Caplan sold 22,346 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the completion of the transaction, the insider now owns 153,544 shares in the company, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Harith Rajagopalan sold 90,972 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the sale, the chief executive officer now owns 491,329 shares in the company, valued at approximately $894,218.78. This represents a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in Fractyl Health in the 3rd quarter valued at about $25,000. Parkside Financial Bank & Trust purchased a new stake in Fractyl Health in the fourth quarter valued at approximately $27,000. Intech Investment Management LLC purchased a new position in Fractyl Health during the fourth quarter worth approximately $34,000. Raymond James Financial Inc. acquired a new position in shares of Fractyl Health in the 4th quarter valued at $34,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Fractyl Health by 335.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after buying an additional 11,406 shares during the period.

Fractyl Health Trading Up 1.3 %

Shares of Fractyl Health stock traded up $0.02 during mid-day trading on Thursday, hitting $1.61. 89,344 shares of the stock were exchanged, compared to its average volume of 306,072. The stock has a market capitalization of $77.44 million and a price-to-earnings ratio of -0.13. Fractyl Health has a twelve month low of $1.37 and a twelve month high of $9.66. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The company has a 50-day simple moving average of $1.76 and a 200 day simple moving average of $2.27.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). Research analysts forecast that Fractyl Health will post -1.61 EPS for the current year.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.